elected 9th directors by the Annual General Shareholders’ meeting of 2024

2.Name and title of the managerial officer with permission

to engage in competitive conduct:

(1)Lee,Tsu-Der：Director

(2)Lu,Ching-Hung：Director

(3)Han,Li-Chun：Independent director

(4)Liang,Chi-Ming：Independent director

3.Items of competitive conduct in which the officer is

permitted to engage:

(1)Lee,Tsu-Der：Director

(a)Diamond Biofund Inc./Vice Chairman and Deputy Chairman of the

Investment Review Committee

(b)Diamond Capital Inc./Representative of institutional director

(2)Lu,Ching-Hung：Director

(a)Microbio Singapore Pte. Ltd/Representative of institutional director

(b)Microbio Malaysia Sdn. Bhd/Representative of institutional director

(c)Diamond Biofund Inc./Vice Chief Strategy Officer

(3)Han,Li-Chun：Independent director

(a)SCI, StemCyte Taiwan Co., Ltd./Independent Director

(b)Sinew Pharma Inc./Independent Director

(c)CHO Pharma, Inc./Member of the Remuneration Committee

(4)Liang,Chi-Ming：Independent director

(a)Yung Shin Pharmaceutical Industrial Co., Ltd./Representative of

institutional director

4.Period of permission to engage in the competitive conduct:

Within period of serving as directors of Company.

5.Circumstances of the resolution (please describe the

results of voting in accordance with Article 209 of the

Company Act):

The total attended voting shares by shareholders:387,843,704; the approval

votes:379,958,827; the disapproval votes:4,245,516; the invalid votes:0; the abstention votes:3,639,361;

The approval votes was 97.96% of the total

attended voting shares. The proposal was therefore approved.

meeting attended by shareholders.

6.If the permitted competitive conduct belongs to the

operator of a mainland China enterprise, the name and

title of the directors (if it is not the operator of

a mainland China enterprise, please enter “N/A” below):N/A

7.Company name of the mainland China enterprise and the

officer’s position in the enterprise:N/A

8.Address of the mainland China enterprise:N/A

9.Operations of the mainland China enterprise:N/A

10.Impact on the company’s finance and business:

(1)Diamond Biofund Inc. is invested by the company and its profits or

losses is recognized by equity method.

(2)Microbio Singapore Pte. Ltd. is invested by the company and its

profits or losses is recognized by equity method.

(3)SCI, StemCyte Taiwan Co., Ltd. is invested by the company and its

profits or losses is recognized by financial assets at fair value

through other comprehensive income – non-current.

11.If the directors have invested in the mainland China

enterprise, the monetary amount of the investment and

their shareholding ratio:N/A

12.Any other matters that need to be specified:None.